New products mean solid revenue may be ahead for these companies.
News & Analysis: Amgen
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Its size, catalog, and pipeline give it strengths that are hard to beat.
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
The failed attempt to repeal and replace Obamacare last month has big implications for healthcare investors.
In this Valentine's Day edition, Industry Focus explores cholesterol busters, heart surgery, and the latest in anticoagulants.
What you should know about Juno Therapeutics' recent cancer trial stop and restart. Also, we help you prep for biopharma's second-quarter earnings deluge.